IM Cannabis (IMCC) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
25 May, 2026Executive summary
Reported Q1 2026 revenues of $8.7 million, with a gross profit of $1.4 million and a net loss of $2.5 million, or $0.38 per share.
Continued focus on cost optimization, operational efficiencies, and working capital discipline.
Convertible note financings completed during and after the quarter supported liquidity.
Financial highlights
Revenue for Q1 2026 was $8.7 million, with a gross profit of $1.4 million.
Operating loss for the quarter was $1.7 million.
Net loss totaled $2.5 million, or $0.38 per share.
General and administrative expenses reduced by 22% year-over-year.
Outlook and guidance
Management remains focused on operational efficiencies and evaluating strategic opportunities for long-term growth.
Continued emphasis on cost optimization and liquidity management.
Latest events from IM Cannabis
- Registering 17.3M shares for resale, with dilution risk and focus on German cannabis market.IMCC
Registration filing - German revenue more than doubled, driving record cash flow and strategic diversification.IMCC
Q4 2025 - Convertible note and warrant offering targets German growth but poses dilution and geopolitical risks.IMCC
Registration Filing - Seeking up to $50M for expansion, with focus on Germany and ongoing risks in Israel.IMCC
Registration Filing - Resale of nearly 5M shares enables capital for growth in Germany and Israel, with Nasdaq listing.IMCC
Registration Filing - Refocused on Germany’s medical cannabis market, with growth funded by recent private placements.IMCC
Registration Filing - Revenue up 12% and adjusted EBITDA loss down 82%, driven by German growth and efficiency.IMCC
Q3 2024 - German legalization drove a 129% sales surge and 12% revenue growth, but margins fell to 6%.IMCC
Q2 2024 - Q4 revenue rose 25% and Germany sales jumped 183%, leading to positive adjusted EBITDA.IMCC
Q4 2024